Compounds and methods for the treatment of EGFR positive diseases

A compound selected from the group consisting of:

• wherein
• X is hydrogen or halo;
• Y is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, and —C(═O)R5;
• R1 is selected from the group consisting of hydrogen, —OH, —OC(═O)R5 and —OR5;
• R2 is hydrogen or C1-C6 alkyl;
• R3 is methyl, —CH2OH, or —CH2C(═O)R6;
• R4 is —OH or —SH;
• R5 is C1-C6 alkyl or benzyl;
• R6 is C1-C6 alkyl, phenyl or benzyl;
• R7 is hydrogen, C1-C6 alkyl or an amino acid side chain;
• R8 is hydrogen or C1-6 alkyl;
• n is 0, 1, 2, 3, 4, 5, 6, 7 or 8;
• or a salt thereof, wherein AA is an amino acid or thiolated amino acid, and wherein the wavy line () represents linkage of the AA through a thioether bond.